Back

Safety of intravenous cangrelor infusion during percutaneous coronary intervention in a real-world cohort of non-pretreated NSTEACS patients

28 August 2022 (16:15 - 17:00)
Organised by:
Congress Presentation Part of: Platelets and more Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Emilio Arbas Redondo

La Paz University Hospital, Madrid (Spain)

8 More presentations in this session

Presentation thumbnail
Clopidogrel monotherapy following dual antiplatelet therapy in patients with acute coronary syndrome post-drug-eluting stent implantation: a systematic review and direct/indirect treatment comparison
Professor D. Sibbing (Munich, DE)
Abstract Slides
Presentation thumbnail
Comparative efficacy and safety of ticagrelor vs. prasugrel in patients undergoing PCI for NSTE-ACS. Results of the prospective ALKK-Registry.
Professor U. Zeymer (Ludwigshafen, DE)
Abstract Slides
Presentation thumbnail
Ticagrelor or prasugrel in patients with acute coronary syndrome and prior myocardial infarction
Doctor M. Scalamogna (Napoly, IT)
Abstract Slides
Presentation thumbnail
Antithrombotic and proton pump inhibitor co-therapy in patients with atrial fibrillation and stable coronary disease: a post hoc analysis of the AFIRE trial
Doctor H. Wada (Izunokuni, JP)
Abstract Slides
Presentation thumbnail
Clinical significance of time-varying on-treatment platelet reactivity after percutaneous coronary intervention
Professor Y. Jeong (Gwangmyeong, KR)
Abstract Slides

Access the full session

Session thumbnail
Platelets and more

The Event

Event poster

ESC Congress 2022

28 August 2022 16:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources